TransMedics Reports Third Quarter 2024 Financial Results

Go back to TransMedics Reports Third Quarter 2024 Financial Results

TransMedics Group (TMDX) PT Lowered to $125 at Oppenheimer

October 29, 2024 6:04 AM EDT

Oppenheimer analyst Suraj Kalia lowered the price target on TransMedics Group (NASDAQ: TMDX) to $125.00 (from $200.00) while maintaining a Outperform rating.

The analyst comments "TransMedics reported 3Q24 revs. of $108.8M, below our/consensus $117.1M/$115.0M estimates. In Q3, our calculated US transplant shares were 21%/27%/4%... More

TransMedics Group (TMDX) Misses Q3 EPS by 17c, Updates Guidance

October 28, 2024 4:11 PM EDT

TransMedics Group (NASDAQ: TMDX) reported Q3 EPS of $0.12, $0.17 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $108.8 million versus the consensus estimate of $114.99 million.

GUIDANCE:

TransMedics Group sees FY2024 revenue of $425-445 million, versus the consensus of... More